[
    "e AR antagonism assay are shown in Table 1. Table 1. AR antagonism </p>Compound of Example No. AR antagonism </p>IC<sub>50</sub> (nM) </p>Ex. 11 cis of 2,5-isomer 26 </p> Ex. 13 60 </p> Ex. 19 c/s-diastereomer 65 </p> Ex. 21 19 </p> Ex. 31 enantiomer 1 73 </p> Ex. 46 ds-enantiomer 2 40 </p> Ex. 48 ris-diastereomer 24 \n\n Ex. 51 enantiomer 2 17</p>Ex. 53 57</p>Ex. 61 35</p>Ex. 63 34</p>Ex. 72 c/s-enantiomer 2 27</p>Ex. 76 c/s-diastereomer 1</p>Ex. 77 40</p>Ex. 83 c/s-diastereomer 16</p>Ex. 84 3,4-isomer 50</p>Ex. 86 trons-enantiomer 1 73</p>Ex. 91 c/s-diastereomer 64</p>Ex. 103 58</p>Ex. 107 51</p>Ex. 130 racemate 65</p>Ex. 132 7</p>Ex. 160 27</p>Ex. 203 enantiomer 1 17.</p>Ex. 208 1,5-isomer 34</p>Ex. 209 c/s-diastereomer 56</p>Ex. 210 23</p>Ex. 216 diastereomer 2 28</p>Ex. 223 79</p>Ex. 226 racemate 29</p>Ex. 227 racemate 57</p>Ex. 232 enantiomer 1 33</p>Ex. 233 enantiomer 1 59</p>Ex. 233 enantiomer 2 29</p>Ex. 236 124</p>Ex. 240(b) 52</p>Ex. 250 205</p>Ex. 252 141</p>Ex. 253(b) 140</p>Ex. 262 89</p>Ex. 270 enantiomer 1 56</p>Ex. 275 63 </p>17.20 Lvase (CYP17) inhibition \n\n The ability of the test compounds to inhibit 17,20 lyase catalysed conversion of 17a-hydroxypregnenolone to dehydroepiandrosterone and acetic acid was measured by acetic acid release assay (AARA) on human H295R adrenocortical carcinoma cell line (Grigoryev, D. N. et al., Analytical Biochemistry 1999; 267:319- 330). The cell line has been shown to express all the key steroidogenic enzymes. To determine the half maximal inhibitory concentration (IC50) of the test compounds on 17,20 lyase inhibition, the cells were treated overnight (16-19 h) with increasing concentrations of the test compounds in the presence of 17a-[21-<sup>3</sup>H]hydroxylpregne- nolone (American Radiolabeled Chemicals). The final DMSO concentration was 1 . Cell culture medium was extracted with dextran-coated charcoal suspension (Isomaa, V. et al., Endocrinology 1982; 11 1(3):833-843). <sup>3</sup>H-acetic acid was determined by mixing 100 \u03bc\u0390 of supernatant fraction in 200 \u03bc\u0390 of scintillation fluid (OptiPhase SuperMix, Perkin Elmer). Radioactivity was measured using a Microbeta scintillation counter (1450 MicroBeta Trilux, Wallac). All the test compounds were studied in quadruplicates. </p>Table 2. 17,20 Lyase (CYP17) inhibition </p>Compound of Example No. CYP17 inhibition </p>ICso (nM) </p>Ex. 2 enantiomer 1 27 </p> Ex. 6 enantiomer 1 74 </p> Ex. 12 c/s-diastereomer 18 </p> Ex. 13 92 </p> Ex. 21 76 </p> Ex. 31 enantiomer 1 23 </p> Ex. 46 c/s-enantiomer 2 49 </p> Ex. 47 c/s-enantiomer 3 18 </p> Ex. 51 enantiomer 2 166 </p> Ex. 53 19 </p> Ex. 61 108 </p> Ex. 63 70 </p> Ex. 84 3,4-isomer 96 </p> Ex. 86 irans-enantiomer 1 27 \n\n</p></p>EXAMPLES: </p> Intermediate Example 1. </p> (l-Ethyl-lH-imidazol-5-yl)boronic acid a) (2-Chloro- l -ethyl- lH-imidazol-5-yl)boronic acid \n\n To a stirred solution of 2-chloro-l -ethyl- IH-imidazole (1.19 g, 9.11 mmol) in dry THF (60 ml) under N<sub>2</sub> (cooled to -78\u00b0C) were added TMEDA (2.04 ml, 13.66 mmol) and 2.5"
]